Charts

~ Data Demonstrates Exceptional Safety Profile of PF614-MPAR, the Industry's First Overdose Protection Pain Product ~

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) has been one of the companies that we cover that we believe most of America is hoping is successful. The opioid crisis remains a plague on the American public and is destroying families and whole communities. The National Institute on Drug Abuse reported more than 106,000 overdose deaths in

In this piece, we will take a look at ten penny stocks with insider buying. For more penny stocks, head on over to 5 Penny Stocks with Insider Buying. With the first quarter of 2023 coming to an end, the stock market continues to be in a topsy-turvy environment. 2023 was off to a strong […]

The Dow Jones rose around 40 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around ...

~ Ensysce Biosciences and Quotient Sciences Showcase a Unique Collaboration ~

The Dow Jones jumped by more than 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or ...

During Tuesday, 79 stocks hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: Johnson & ...

Company Remains on Track to Report Results the End of March

Answers Recently Asked Questions

Gainers Community Health Systems (NYSE:CYH) shares moved upwards by 24.0% to $6.3 during Wednesday's after-market session. At the ...

SAN DIEGO, CA / ACCESSWIRE / February 15, 2023 / Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that by decision dated February 14, 2023, a Nasdaq Hearings Panel (the "Panel") granted the Company's request for continued listing on The Nasdaq Stock Market ("Nasdaq"), subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market tier, including the $1.00 bid price and $2.5 million stockholders' equity requirements, by June 12, 2023, and the Company's satisfaction of certain other interim conditions.

SAN DIEGO, CA / ACCESSWIRE / February 14, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced a Poster Presentation will be presented by Geoff Birkett, Chief Commercial Officer of Ensysce, at the Annual NIH HEAL Meeting on February 22, 2023, in Washington, D.C.

SAN DIEGO, CA / ACCESSWIRE / February 7, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 3,571,431 shares of the Company's common stock at a purchase price of $0.84 per share of common stock in a registered direct offering priced at-the-market under NASDAQ rules.

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is committed to finding a solution to the opioid crisis plaguing the US and other developed countries around the world. Through its proprietary TAAP technology Ensysce is in the process of receiving approval for an abuse-resistant yet still pain-relieving opioid. The company continues to

SAN DIEGO, CA / ACCESSWIRE / February 3, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has entered into a definitive agreement for the purchase and sale of 3,571,431 shares of the Company's common stock at a purchase price of $0.84 per share of common stock in a registered direct offering priced at-the-marked under Nasdaq rules.

The Federal Reserve on Wednesday raised its benchmark rate by 0.25%, marking the central bank's second consecutive policy downshift. ...

SAN DIEGO, CA / ACCESSWIRE / February 1, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that its Board of Directors has declared a dividend of 0.001 of a share of newly-designated Series A Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on February 13, 2023. The outstanding shares of Series A Preferred Stock will vote together with the outstanding shares of the Company's common stock, as a single class, exclusively with respect to a reverse stock split, as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the reverse stock split, and will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law. Subject to certain limitations, each outstanding share of Series A Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per 0.001 of a share of Series A Preferred Stock).

Ensysce Biosciences Inc (NASDAQ: ENSC) shares are trading higher by 21.81% to $0.82 Wednesday after the company announced initiation of ...

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 50 points on Wednesday. The Dow traded ...

Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares surged 85% to $2.2200. Sonoma Pharmaceuticals and EMC Pharma announced ...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 200 points on Wednesday. The Dow traded ...

Gainers Geovax Labs (NASDAQ:GOVX) shares moved upwards by 62.8% to $1.14 during Wednesday's regular session. As of 12:30 EST, Geovax ...

~ PF614-MPAR to be the Industry's First Overdose Protection Pain Product ~

SAN DIEGO, CA / ACCESSWIRE / January 23, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that Chief Executive Officer, Dr. Lynn Kirkpatrick, will present a company overview at the Diamond Equity Research 2023 Virtual Emerging Growth Invitational on Wednesday, January 25th, 2023, at 12:20 p.m. Eastern Time. Following the presentation, Dr. Kirkpatrick will take questions from participants.

Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Spotlight Emerging Growth Invitational Investor Conference on January 25, 2023. The conference, which is open to all retail and institutional investors, will consist of a series of twenty-five-m

Gainers SmileDirectClub (NASDAQ:SDC) stock increased by 47.0% to $0.71 during Monday's regular session. SmileDirectClub's stock is ...

Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) stock rose 90.6% to $8.5 during Friday's regular session. As of 12:30 EST, TC BioPharm ...

Gainers Yield10 Bioscience (NASDAQ:YTEN) shares increased by 35.2% to $2.84 during Thursday's regular session. Trading volume for ...

SAN DIEGO, CA / ACCESSWIRE / January 11, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick.

Ensysce Biosciences's (NASDAQ:ENSC) short percent of float has fallen 83.99% since its last report. The company recently reported ...

Data Expected in March 2023

Gainers Novo Integrated Sciences (NASDAQ:NVOS) stock rose 8.3% to $0.2 during Tuesday's after-market session. Today's trading volume ...

Benzinga Pro data, Ensysce Biosciences (NASDAQ:ENSC) reported Q3 sales of $279 thousand. Earnings fell to a loss of $9.86 million, ...

OnFriday, 143 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest company by ...

Ensysce Biosciences's (NASDAQ:ENSC) short percent of float has risen 128.73% since its last report. The company recently reported ...

Gainers Metacrine (NASDAQ:MTCR) stock increased by 27.0% to $0.45 during Monday's after-market session. Today's trading volume for this ...

~ PF614-MPAR will be the Industry's First Overdose Protection Pain Product ~

On Wednesday, 115 stocks hit new 52-week lows. Noteable 52-Week Lows: The largest company by market cap to hit a new ...

NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Ensysce Biosciences, Inc. (NASDAQ: ENSC). The in-depth 21-page initiation report includes detailed information on the Ensysce Biosciences’ business model, services, industry, valuation, management, and risks. The full research report is available here. Highlights from the report include: Unique and Extensible Technolog

Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG ...

Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares rose 104% to $7.00 in pre-market trading. Aptevo Therapeutics said 100% ...

Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results ...

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage pharmaceutical company that is attempting to attack the plague of opioid abuse, while still allowing for the pain relief that so many people desperately need. Ensysce’s goal is to tackle both the problem of widespread abuse of prescription opioids and also the issue of the

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 0.5% on Wednesday. The Dow traded up ...

Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for ...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping 75 points on Wednesday. The Dow traded down 0.22% ...

Ensysce Biosciences Inc (NASDAQ: ENSC) shares are trading lower by 51.12% to $1.09 Wednesday morning after the comnpany announced ...

U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 50 points on Wednesday. Following the market opening ...

Gainers Prometheus Biosciences (NASDAQ:RXDX) stock rose 182.9% to $102.0 during Wednesday's pre-market session. The company's market ...

SAN DIEGO, CA / ACCESSWIRE / December 7, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC),(OTC PINK: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the pricing of an underwritten public offering of 2,900,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 5,800,000 shares of common stock at a combined effective public offering price of $1.40 per share of common stock (or pre-funded warrant) and accompanying warrants. Each warrant is exercisable immediately at an exercise price of $1.40 per share and will expire five years following the date of issuance. The Company expects to receive aggregate gross proceeds of approximately $4.1 million from the offering. The offering is expected to close on or about December 9, 2022, subject to satisfaction of customary closing conditions.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time for another dive into the biggest pre-market stock movers as we check out the latest news traders need to know about on Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Ensysce Biosciences Inc (NASDAQ: ENSC) shares are trading higher by 5.12% to $2.26Monday morning after the company announced that ...

~ Completion of Trial Represents Continuing Progress Towards Development of the Industry's First Overdose Protection Pain Product ~